Survival Analysis Basics
Author Information
Author(s): Clark T G, Bradburn M J, Love S B, Altman D G
Primary Institution: Cancer Research UK/NHS Centre for Statistics in Medicine, Institute of Health Sciences, University of Oxford
Conclusion
Survival analysis is essential for understanding time-to-event data in cancer studies, particularly due to the challenges posed by censoring.
Supporting Evidence
- 75.9% of patients in the ovarian cancer study died by the end of follow-up.
- The combination treatment group had a median survival time of 1.10 years compared to 0.64 years for radiotherapy alone.
- A logrank test showed significant differences in survival between treatment groups.
Takeaway
This study explains how to analyze survival times in cancer patients, which helps doctors understand how long patients might live after treatment.
Methodology
The paper discusses survival analysis methods including Kaplan-Meier plots and logrank tests.
Potential Biases
Potential bias due to unequal follow-up among different treatment groups.
Limitations
The study may not account for informative censoring, which can bias results.
Participant Demographics
Patients diagnosed with primary epithelial ovarian carcinoma and those with non-small cell lung cancer.
Statistical Information
P-Value
<0.002
Confidence Interval
95% CI: 0.45–0.87 for radiotherapy, 95% CI: 0.96–1.59 for combination therapy
Statistical Significance
p<0.002
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website